Cochrane · systematic review · CD005162
Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
Allegretti, AS, Israelsen, M, Krag, A, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Terlipressin versus placebo or no intervention for hepatorenal syndrome
Population: people with hepatorenal syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Terlipressin vs placebo or no intervention | RR 0.85 [0.73, 0.98] | 9 studies · 534 participants | Low |
Hepatorenal syndrome Terlipressin vs placebo or no intervention | RR 0.63 [0.48, 0.82] | 7 studies · 510 participants | Low |
Serious adverse events Terlipressin vs placebo or no intervention | RR 0.91 [0.68, 1.21] | 9 studies · 534 participants | Low |
Serious cardiovascular adverse events Terlipressin vs placebo or no intervention | RR 7.26 [1.7, 31.05] | 4 studies · 234 participants | Low |
Abdominal pain Terlipressin vs placebo or no intervention | RR 1.54 [0.97, 2.43] | 4 studies · 294 participants | Low |
Diarrhoea Terlipressin vs placebo or no intervention | RR 5.76 [2.19, 15.15] | 2 studies · 240 participants | Low |